董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Scott W. Morrison | 男 | Independent Director | 68 | 9.96万美元 | 未持股 | 2025-10-02 |
| David Moore | -- | Director | -- | 未披露 | 未持股 | 2025-10-02 |
| Richard A. van den Broek | 男 | Director | 59 | 未披露 | 未持股 | 2025-10-02 |
| Richard A. Miller | 男 | President, Chief Executive Officer and Chairman of the Board | 73 | 109.80万美元 | 未持股 | 2025-10-02 |
| Ian T. Clark | 男 | Independent Director | 64 | 8.36万美元 | 未持股 | 2025-10-02 |
| Peter Thompson | 男 | Independent Director | 65 | 8.56万美元 | 未持股 | 2025-10-02 |
| Linda S. Grais | 女 | Independent Director | 69 | 15.63万美元 | 未持股 | 2025-10-02 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Leiv Lea | 男 | Chief Financial Officer and Principal Accounting Officer | 72 | 74.98万美元 | 未持股 | 2025-10-02 |
| William B. Jones | 男 | Senior Vice President, Pharmaceutical Development | 60 | 35.75万美元 | 未持股 | 2025-10-02 |
| Jeffrey Arcara | 男 | Senior Vice President and Chief Business Officer | 56 | 未披露 | 未持股 | 2025-10-02 |
| Richard A. Miller | 男 | President, Chief Executive Officer and Chairman of the Board | 73 | 109.80万美元 | 未持股 | 2025-10-02 |
董事简历
中英对照 | 中文 | 英文- Scott W. Morrison
-
Scott W. Morrison，曾担任Corvus Pharmaceuticals， Inc.的成员。自2015年12月起担任董事会成员。从1996年到2015年12月，他是Ernst & Young LLP（一家公共会计师事务所）的合伙人，在那里他还担任美国生命科学领导者（从2002年到2015年12月）。自2022年10月起，他还担任公共生物技术公司Tarsus Pharmaceuticals， Inc.的董事会成员；自2018年7月起，担任公共生物制药公司Ideaya Biosciences， Inc.的董事会成员；自2021年10月起，担任Zai Labs， Inc.的董事会成员；自2020年4月起，担任公共生物制药公司Vera Therapeutics， Inc.的董事会成员。他曾担任许多生命科学行业组织的董事会成员。此前，他曾任职于生命科学基金会（生物技术非营利组织）、湾区生物科学协会（501（c）（3）组织）和生物技术创新组织（贸易组织）的新兴公司部门的董事会。他持有加州大学伯克利分校工商管理学士学位，是一名注册会计师（非活跃）。
Scott W. Morrison,has served as a member of Corvus Pharmaceuticals, Inc. Board since December 2015. From 1996 to December 2015, Mr. Morrison was a Partner with Ernst & Young LLP, a public accounting firm, where he also served as U.S. Life Sciences Leader from 2002 to December 2015. He also serves on the board of directors of Tarsus Pharmaceuticals, Inc., a public biotechnology company, since October 2022 on the board of directors of Ideaya Biosciences, Inc., a public biopharmaceutical company, since July 2018 on the board of Zai Labs, Inc., a public biotech company since October 2021 and on the board of directors of Vera Therapeutics, Inc., a public biopharmaceutical company, since April 2020. Mr. Morrison has held roles on the boards of directors of numerous life sciences industry organizations. Mr. Morrison has previously served on the boards of directors of the Life Sciences Foundation, a biotechnology non-profit organization, the Bay Area Biosciences Association, a 501(c)(3) organization, and the Emerging Companies Section of the Biotechnology Innovation Organization, a trade organization. He received a B.S. in Business Administration from the University of California-Berkeley and is a certified public accountant (inactive). - Scott W. Morrison，曾担任Corvus Pharmaceuticals， Inc.的成员。自2015年12月起担任董事会成员。从1996年到2015年12月，他是Ernst & Young LLP（一家公共会计师事务所）的合伙人，在那里他还担任美国生命科学领导者（从2002年到2015年12月）。自2022年10月起，他还担任公共生物技术公司Tarsus Pharmaceuticals， Inc.的董事会成员；自2018年7月起，担任公共生物制药公司Ideaya Biosciences， Inc.的董事会成员；自2021年10月起，担任Zai Labs， Inc.的董事会成员；自2020年4月起，担任公共生物制药公司Vera Therapeutics， Inc.的董事会成员。他曾担任许多生命科学行业组织的董事会成员。此前，他曾任职于生命科学基金会（生物技术非营利组织）、湾区生物科学协会（501（c）（3）组织）和生物技术创新组织（贸易组织）的新兴公司部门的董事会。他持有加州大学伯克利分校工商管理学士学位，是一名注册会计师（非活跃）。
- Scott W. Morrison,has served as a member of Corvus Pharmaceuticals, Inc. Board since December 2015. From 1996 to December 2015, Mr. Morrison was a Partner with Ernst & Young LLP, a public accounting firm, where he also served as U.S. Life Sciences Leader from 2002 to December 2015. He also serves on the board of directors of Tarsus Pharmaceuticals, Inc., a public biotechnology company, since October 2022 on the board of directors of Ideaya Biosciences, Inc., a public biopharmaceutical company, since July 2018 on the board of Zai Labs, Inc., a public biotech company since October 2021 and on the board of directors of Vera Therapeutics, Inc., a public biopharmaceutical company, since April 2020. Mr. Morrison has held roles on the boards of directors of numerous life sciences industry organizations. Mr. Morrison has previously served on the boards of directors of the Life Sciences Foundation, a biotechnology non-profit organization, the Bay Area Biosciences Association, a 501(c)(3) organization, and the Emerging Companies Section of the Biotechnology Innovation Organization, a trade organization. He received a B.S. in Business Administration from the University of California-Berkeley and is a certified public accountant (inactive).
- David Moore
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Richard A. van den Broek
-
Richard A. van den Broek先生在2009年12月加盟本公司，担任董事。自2004年起，van den Broek先生一直是HSMR顾问有限责任公司（HSMR Advisors, LLC）的管理合伙人，该公司是一家专注于生物技术产业投资基金公司。从2000年到2003年，他曾是Cooper Hill Partners有限责任公司的合伙人，该公司是一家专注于医疗保健行业的投资基金的公司。在此之前，van den Broek先生有担任了10年的生物技术分析师，一开始他是在奥本海默公司（Oppenheimer & Co.），之后他进入了美林公司（Merrill Lynch），最后是进入了汉鼎公司（Merrill Lynch）工作。van den Broek先生是特别多元机遇公司（Special Diversified Opportunities, Inc.）的董事，也是Response Genetics公司薪酬委员会的成员兼公司董事。他也是CogState公司（CogState, Ltd.）的董事兼薪酬委员会成员，该公司是一家澳大利亚的上市公司。他是哈佛大学（Harvard University ）的毕业生，是一名特许金融分析师。
Richard A. van den Broek was appointed to Board of Directors in Augt 2020. Mr. van den Broek currently serves as managing partner of HSMR Advisors, LLC, a position he has held since February 2004, and has served as a director of PhaseBio Pharmaceuticals, Inc. since February 2019 and Cogstate Ltd since 2009. Mr. van den Broek previoly served on the boards of directors of Pharmacyclics, Inc., from December 2009 to April 2015, Response Genetics, Inc., from December 2010 to September 2015, Special Diversified Opportunities, Inc., from March 2008 to October 2015, and Celldex Therapeutics, Inc., from December 2014 to December 2016. Mr. van den Broek received an A.B. from Harvard University and is a Chartered Financial Analyst. - Richard A. van den Broek先生在2009年12月加盟本公司，担任董事。自2004年起，van den Broek先生一直是HSMR顾问有限责任公司（HSMR Advisors, LLC）的管理合伙人，该公司是一家专注于生物技术产业投资基金公司。从2000年到2003年，他曾是Cooper Hill Partners有限责任公司的合伙人，该公司是一家专注于医疗保健行业的投资基金的公司。在此之前，van den Broek先生有担任了10年的生物技术分析师，一开始他是在奥本海默公司（Oppenheimer & Co.），之后他进入了美林公司（Merrill Lynch），最后是进入了汉鼎公司（Merrill Lynch）工作。van den Broek先生是特别多元机遇公司（Special Diversified Opportunities, Inc.）的董事，也是Response Genetics公司薪酬委员会的成员兼公司董事。他也是CogState公司（CogState, Ltd.）的董事兼薪酬委员会成员，该公司是一家澳大利亚的上市公司。他是哈佛大学（Harvard University ）的毕业生，是一名特许金融分析师。
- Richard A. van den Broek was appointed to Board of Directors in Augt 2020. Mr. van den Broek currently serves as managing partner of HSMR Advisors, LLC, a position he has held since February 2004, and has served as a director of PhaseBio Pharmaceuticals, Inc. since February 2019 and Cogstate Ltd since 2009. Mr. van den Broek previoly served on the boards of directors of Pharmacyclics, Inc., from December 2009 to April 2015, Response Genetics, Inc., from December 2010 to September 2015, Special Diversified Opportunities, Inc., from March 2008 to October 2015, and Celldex Therapeutics, Inc., from December 2014 to December 2016. Mr. van den Broek received an A.B. from Harvard University and is a Chartered Financial Analyst.
- Richard A. Miller
-
Richard A. Miller，曾担任Corvus Pharmaceuticals， Inc.自2014年2月起担任Corvus Pharmaceuticals， Inc.的总裁兼首席执行官。自2014年1月起担任董事会成员，并共同创立了公司。从2012年4月到2014年10月，Miller博士担任Graphea， Inc.（他创立的私人控股化学公司）的董事长兼首席执行官。2010年9月至2011年12月，Miller博士担任The University of Texas at Austin的首席商业化官、副院长和化学研究教授。2009年1月至2011年2月，Miller博士创立了私人生物制药公司Principia Biopharma Inc.，并担任其总裁兼首席执行官和董事会成员。他曾担任Pharmacyclics， Inc.（一家公共生物制药公司）的总裁、首席执行官和董事（从1991年他共同创立该公司到2008年）。在Pharmacyclics， Miller博士领导了ibrutinib的最初发现和开发工作。Miller博士是IDEC制药公司（一家生物技术公司，于2003年6月与Biogen公司合并）的联合创始人、副总裁兼董事，在那里他领导了淋巴瘤的研究工作，导致了rituximab的开发。从1991年到2023年，Miller博士一直担任斯坦福大学医学中心的肿瘤学兼职临床教授。他持有Franklin & Marshall College的化学学士学位，以及New York State大学 Medical School的以优异成绩获得的医学博士学位。他是内科和肿瘤学的董事会认证。
Richard A. Miller,has served as Corvus Pharmaceuticals, Inc. President and Chief Executive Officer since February 2014 and chairman of Corvus Pharmaceuticals, Inc. Board since January 2014 and co-founded the Company. From April 2012 to October 2014, Dr. Miller was Chairman and Chief Executive Officer of Graphea, Inc., a privately held chemical company, which he founded. Dr. Miller served as Chief Commercialization Officer, Associate Dean and Research Professor in Chemistry at The University of Texas at Austin from September 2010 to December 2011. Dr. Miller founded Principia Biopharma Inc., a privately held biopharmaceutical company, and served as its President and Chief Executive Officer and a member of its board of directors from January 2009 to February 2011. He served as President, Chief Executive Officer and Director of Pharmacyclics, Inc., a public biopharmaceutical company, from 1991, when he co founded the company, to 2008. At Pharmacyclics, Dr. Miller led the initial discovery and development efforts for ibrutinib. Dr. Miller was a co founder, Vice President and Director of IDEC Pharmaceuticals Corporation, a biotechnology company that merged with Biogen, Inc. in June 2003, where he led research efforts on lymphoma leading to the development of rituximab. Dr. Miller has been Adjunct Clinical Professor of Medicine (Oncology) at Stanford University Medical Center from 1991 to 2023. Dr. Miller received a B.A. in Chemistry from Franklin & Marshall College and an M.D. summa cum laude from the State University of New York Medical School. He is board certified in both Internal Medicine and Medical Oncology. - Richard A. Miller，曾担任Corvus Pharmaceuticals， Inc.自2014年2月起担任Corvus Pharmaceuticals， Inc.的总裁兼首席执行官。自2014年1月起担任董事会成员，并共同创立了公司。从2012年4月到2014年10月，Miller博士担任Graphea， Inc.（他创立的私人控股化学公司）的董事长兼首席执行官。2010年9月至2011年12月，Miller博士担任The University of Texas at Austin的首席商业化官、副院长和化学研究教授。2009年1月至2011年2月，Miller博士创立了私人生物制药公司Principia Biopharma Inc.，并担任其总裁兼首席执行官和董事会成员。他曾担任Pharmacyclics， Inc.（一家公共生物制药公司）的总裁、首席执行官和董事（从1991年他共同创立该公司到2008年）。在Pharmacyclics， Miller博士领导了ibrutinib的最初发现和开发工作。Miller博士是IDEC制药公司（一家生物技术公司，于2003年6月与Biogen公司合并）的联合创始人、副总裁兼董事，在那里他领导了淋巴瘤的研究工作，导致了rituximab的开发。从1991年到2023年，Miller博士一直担任斯坦福大学医学中心的肿瘤学兼职临床教授。他持有Franklin & Marshall College的化学学士学位，以及New York State大学 Medical School的以优异成绩获得的医学博士学位。他是内科和肿瘤学的董事会认证。
- Richard A. Miller,has served as Corvus Pharmaceuticals, Inc. President and Chief Executive Officer since February 2014 and chairman of Corvus Pharmaceuticals, Inc. Board since January 2014 and co-founded the Company. From April 2012 to October 2014, Dr. Miller was Chairman and Chief Executive Officer of Graphea, Inc., a privately held chemical company, which he founded. Dr. Miller served as Chief Commercialization Officer, Associate Dean and Research Professor in Chemistry at The University of Texas at Austin from September 2010 to December 2011. Dr. Miller founded Principia Biopharma Inc., a privately held biopharmaceutical company, and served as its President and Chief Executive Officer and a member of its board of directors from January 2009 to February 2011. He served as President, Chief Executive Officer and Director of Pharmacyclics, Inc., a public biopharmaceutical company, from 1991, when he co founded the company, to 2008. At Pharmacyclics, Dr. Miller led the initial discovery and development efforts for ibrutinib. Dr. Miller was a co founder, Vice President and Director of IDEC Pharmaceuticals Corporation, a biotechnology company that merged with Biogen, Inc. in June 2003, where he led research efforts on lymphoma leading to the development of rituximab. Dr. Miller has been Adjunct Clinical Professor of Medicine (Oncology) at Stanford University Medical Center from 1991 to 2023. Dr. Miller received a B.A. in Chemistry from Franklin & Marshall College and an M.D. summa cum laude from the State University of New York Medical School. He is board certified in both Internal Medicine and Medical Oncology.
- Ian T. Clark
-
Ian T. Clark，曾担任Corvus Pharmaceuticals， Inc.的成员。自2017年1月起担任董事会成员。Clark先生在生物技术和制药行业拥有超过35年的经验，最近担任Genentech的首席执行官和董事会成员，直到他于2016年12月退休。在他担任首席执行官的7年任期内，Clark先生和他的团队向市场推出了11种新药，用于治疗类风湿性关节炎、特发性肺纤维化和各种类型的癌症。Clark先生被Glassdoor评为最高评级的首席执行官之一，被旧金山商业时报评为湾区最受尊敬的首席执行官，并被Heath Business Woman's Association授予年度荣誉导师。在加入Genentech之前，Clark先生在美国、英国、加拿大、东欧和法国的诺华（Novartis）、赛诺菲（Sanofi）、伊瓦克斯（Ivax）和塞尔（Searle）担任各种职务，责任越来越大。目前，他是几家上市生物制药和生物技术公司的董事会成员：Takeda Pharmaceutical Company Limited、Guardant Health， Inc.、Olema Oncology和Kyverna Therapeutics， Inc.。Clark先生曾任职于Forty - Seven Inc.、Shire Pharmaceuticals, Inc.、Kite Pharma, Inc.、Agios Pharmaceuticals, Inc.和Avrobio， Inc.的董事会。他也是生物技术行业协会的董事会成员，联邦储备第12区经济顾问委员会成员，以及格拉德斯通研究所的BioFulcrum董事会成员。Clark先生在英国Southampton大学获得生物科学学士学位和荣誉科学博士学位。
Ian T. Clark,has served as a member of Corvus Pharmaceuticals, Inc. Board since January 2017. Mr. Clark has more than 35 years of experience in the biotechnology and pharmaceutical industry, most recently serving as CEO and member of the board of directors for Genentech, until his retirement in December 2016. During his seven-year tenure as CEO, Mr. Clark and his team brought eleven new medicines to market for patients fighting rheumatoid arthritis, idiopathic pulmonary fibrosis and various types of cancer. Mr. Clark was among the highest rated CEOs by Glassdoor, recognized as the Bay Area's most admired CEO by the San Francisco Business Times and awarded the Honorable Mentor of the Year by the Heath Business Woman's Association. Prior to joining Genentech, Mr. Clark held various positions of increasing responsibility at Novartis, Sanofi, Ivax and Searle, working in the USA, UK, Canada, Eastern Europe and France. Currently, Mr. Clark is on the board of directors of several public biopharmaceutical and biotechnology companies: Takeda Pharmaceutical Company Limited, Guardant Health, Inc., Olema Oncology and Kyverna Therapeutics, Inc. Mr. Clark previously served on the Boards of Forty Seven Inc., Shire Pharmaceuticals, Inc., Kite Pharma, Inc., Agios Pharmaceuticals, Inc. and Avrobio, Inc. He was also on the Board of Biotechnology Industry Association, on the Economic Advisory Council of the 12th District of the Federal Reserve and on the BioFulcrum Board of the Gladstone Institute. Mr. Clark received his Bachelor of Science in Biological Sciences and an Honorary Doctorate of Science from Southampton University in the United Kingdom. - Ian T. Clark，曾担任Corvus Pharmaceuticals， Inc.的成员。自2017年1月起担任董事会成员。Clark先生在生物技术和制药行业拥有超过35年的经验，最近担任Genentech的首席执行官和董事会成员，直到他于2016年12月退休。在他担任首席执行官的7年任期内，Clark先生和他的团队向市场推出了11种新药，用于治疗类风湿性关节炎、特发性肺纤维化和各种类型的癌症。Clark先生被Glassdoor评为最高评级的首席执行官之一，被旧金山商业时报评为湾区最受尊敬的首席执行官，并被Heath Business Woman's Association授予年度荣誉导师。在加入Genentech之前，Clark先生在美国、英国、加拿大、东欧和法国的诺华（Novartis）、赛诺菲（Sanofi）、伊瓦克斯（Ivax）和塞尔（Searle）担任各种职务，责任越来越大。目前，他是几家上市生物制药和生物技术公司的董事会成员：Takeda Pharmaceutical Company Limited、Guardant Health， Inc.、Olema Oncology和Kyverna Therapeutics， Inc.。Clark先生曾任职于Forty - Seven Inc.、Shire Pharmaceuticals, Inc.、Kite Pharma, Inc.、Agios Pharmaceuticals, Inc.和Avrobio， Inc.的董事会。他也是生物技术行业协会的董事会成员，联邦储备第12区经济顾问委员会成员，以及格拉德斯通研究所的BioFulcrum董事会成员。Clark先生在英国Southampton大学获得生物科学学士学位和荣誉科学博士学位。
- Ian T. Clark,has served as a member of Corvus Pharmaceuticals, Inc. Board since January 2017. Mr. Clark has more than 35 years of experience in the biotechnology and pharmaceutical industry, most recently serving as CEO and member of the board of directors for Genentech, until his retirement in December 2016. During his seven-year tenure as CEO, Mr. Clark and his team brought eleven new medicines to market for patients fighting rheumatoid arthritis, idiopathic pulmonary fibrosis and various types of cancer. Mr. Clark was among the highest rated CEOs by Glassdoor, recognized as the Bay Area's most admired CEO by the San Francisco Business Times and awarded the Honorable Mentor of the Year by the Heath Business Woman's Association. Prior to joining Genentech, Mr. Clark held various positions of increasing responsibility at Novartis, Sanofi, Ivax and Searle, working in the USA, UK, Canada, Eastern Europe and France. Currently, Mr. Clark is on the board of directors of several public biopharmaceutical and biotechnology companies: Takeda Pharmaceutical Company Limited, Guardant Health, Inc., Olema Oncology and Kyverna Therapeutics, Inc. Mr. Clark previously served on the Boards of Forty Seven Inc., Shire Pharmaceuticals, Inc., Kite Pharma, Inc., Agios Pharmaceuticals, Inc. and Avrobio, Inc. He was also on the Board of Biotechnology Industry Association, on the Economic Advisory Council of the 12th District of the Federal Reserve and on the BioFulcrum Board of the Gladstone Institute. Mr. Clark received his Bachelor of Science in Biological Sciences and an Honorary Doctorate of Science from Southampton University in the United Kingdom.
- Peter Thompson
-
Peter Thompson，曾担任Corvus Pharmaceuticals， Inc.的成员。自2014年11月担任董事会成员，并共同创立了公司。Thompson博士是投资公司OrbiMed Advisors LLC的成员。Thompson博士目前担任ARS Pharmaceuticals， Inc.（原Silverback Therapeutics， Inc.）， Edgewise Therapeutics, Inc.和Sionna Therapeutics， Inc.以及几家私人公司的董事会成员。此前，Thompson博士担任Alpine Immune Sciences， Inc.、分贝治疗公司、Janux Therapeutics， Inc.、PMV Pharmaceuticals, Inc.和precpretherapeutics Inc.的董事会成员。Thompson博士此前还曾担任Trubion Pharmaceuticals， Inc.、Chiron Corporation和Becton， Dickinson and Company的执行领导职务。Thompson博士是华盛顿大学神经外科副教授。此外，Thompson博士拥有多项专利，是董事会认证的内科医生和肿瘤学家。他持有Brown大学的分子生物学和数学学士学位，以及Brown大学Medical School的医学博士学位。
Peter Thompson,is a Partner at OrbiMed Advisors LLC, an investment firm focused on the healthcare sector, where he previously served as a Venture Partner since joining in September 2010. Dr. Thompson is also the Chairman of Terremoto Biosciences, Inc., a biotechnology company developing targeted therapeutics, since August 2024, where he previously served as President and Chief Executive Officer from August 2021 to August 2024. Dr. Thompson previously served as Chief Executive Officer and President of two private companies: Glia Biotherapeutics, Inc., a biopharmaceutical company targeting glia-mediated pathways from July 2018 to July 2023 and Terremoto Therapeutics Holdings, LLC, a drug discovery and development company from August 2021 to December 2022. Dr. Thompson currently serves on the boards of directors of several public companies, including Sionna Therapeutics, Inc. (since February 2022), Corvus Pharmaceuticals, Inc. (since November 2014), and ARS Pharmaceuticals Inc. (since April 2016). Dr. Thompson has previously served on the boards of directors of Alpine Immune Sciences, Inc., Janux Therapeutics, Inc., Decibel Therapeutics, Inc., Adaptimmune Therapeutics PLC, Principia Biopharma Inc., PMV Pharmaceuticals, Inc., Prevail Therapeutics, Inc., Sierra Oncology, Inc., and Synthorx Inc. Dr. Thompson also currently serves on the board of directors of several private companies. Dr. Thompson co-founded Silverback Therapeutics, Inc. and Cleave Biosciences Inc. Dr. Thompson also previously served in executive leadership roles at Trubion Pharmaceuticals, Inc., Chiron Corporation, and Becton, Dickinson and Company. Dr. Thompson is an Affiliate Professor of Neurosurgery at the University of Washington. In addition, Dr. Thompson holds numerous patents and is a board-certified internist and oncologist. Dr. Thompson received a Sc. B. in Molecular Biology and Mathematics from Brown University and an M.D. from Brown University Medical School. - Peter Thompson，曾担任Corvus Pharmaceuticals， Inc.的成员。自2014年11月担任董事会成员，并共同创立了公司。Thompson博士是投资公司OrbiMed Advisors LLC的成员。Thompson博士目前担任ARS Pharmaceuticals， Inc.（原Silverback Therapeutics， Inc.）， Edgewise Therapeutics, Inc.和Sionna Therapeutics， Inc.以及几家私人公司的董事会成员。此前，Thompson博士担任Alpine Immune Sciences， Inc.、分贝治疗公司、Janux Therapeutics， Inc.、PMV Pharmaceuticals, Inc.和precpretherapeutics Inc.的董事会成员。Thompson博士此前还曾担任Trubion Pharmaceuticals， Inc.、Chiron Corporation和Becton， Dickinson and Company的执行领导职务。Thompson博士是华盛顿大学神经外科副教授。此外，Thompson博士拥有多项专利，是董事会认证的内科医生和肿瘤学家。他持有Brown大学的分子生物学和数学学士学位，以及Brown大学Medical School的医学博士学位。
- Peter Thompson,is a Partner at OrbiMed Advisors LLC, an investment firm focused on the healthcare sector, where he previously served as a Venture Partner since joining in September 2010. Dr. Thompson is also the Chairman of Terremoto Biosciences, Inc., a biotechnology company developing targeted therapeutics, since August 2024, where he previously served as President and Chief Executive Officer from August 2021 to August 2024. Dr. Thompson previously served as Chief Executive Officer and President of two private companies: Glia Biotherapeutics, Inc., a biopharmaceutical company targeting glia-mediated pathways from July 2018 to July 2023 and Terremoto Therapeutics Holdings, LLC, a drug discovery and development company from August 2021 to December 2022. Dr. Thompson currently serves on the boards of directors of several public companies, including Sionna Therapeutics, Inc. (since February 2022), Corvus Pharmaceuticals, Inc. (since November 2014), and ARS Pharmaceuticals Inc. (since April 2016). Dr. Thompson has previously served on the boards of directors of Alpine Immune Sciences, Inc., Janux Therapeutics, Inc., Decibel Therapeutics, Inc., Adaptimmune Therapeutics PLC, Principia Biopharma Inc., PMV Pharmaceuticals, Inc., Prevail Therapeutics, Inc., Sierra Oncology, Inc., and Synthorx Inc. Dr. Thompson also currently serves on the board of directors of several private companies. Dr. Thompson co-founded Silverback Therapeutics, Inc. and Cleave Biosciences Inc. Dr. Thompson also previously served in executive leadership roles at Trubion Pharmaceuticals, Inc., Chiron Corporation, and Becton, Dickinson and Company. Dr. Thompson is an Affiliate Professor of Neurosurgery at the University of Washington. In addition, Dr. Thompson holds numerous patents and is a board-certified internist and oncologist. Dr. Thompson received a Sc. B. in Molecular Biology and Mathematics from Brown University and an M.D. from Brown University Medical School.
- Linda S. Grais
-
Linda S. Grais，自2019年1月起担任Corvus Pharmaceuticals, Inc.董事会成员。Grais博士此前于2012年6月至2017年12月担任Ocera医疗公司总裁兼首席执行官，并于2008年1月至2017年12月担任公司董事会成员。在加入Ocera之前，Grais博士曾于2005年5月至2011年2月担任风险投资公司InterWest Partners的管理成员。从1998年7月到2003年7月，Grais博士是SGX Pharmaceuticals Inc.的创始人和执行副总裁，SGX Pharmaceuticals Inc.是一家专注于癌症新疗法的药物发现公司。在此之前，她是Wilson Sonsini Goodrich & Rosati的公司律师，在风险融资、公开发行和战略合作伙伴关系等领域执业。在从事法律工作之前，Grais博士曾在加州大学旧金山分校担任内科和重症监护的临床助理教授。她目前在公共合同研究机构ICON plc、私营医疗保健服务公司Collective Health和私营生物技术公司Iolyx Therapeutics，Inc.的董事会任职。Grais博士获得了耶鲁大学的学士学位、耶鲁大学医学院的医学博士学位和斯坦福大学法学院的法学博士学位。
Linda S. Grais,has served as a member of Corvus Pharmaceuticals, Inc. Board since January 2019. Dr. Grais previously served as President and Chief Executive Officer of Ocera Therapeutics, Inc. from June 2012 to December 2017 and as a member of its board of directors from January 2008 through December 2017. Prior to her employment by Ocera, Dr. Grais served as a managing member at InterWest Partners, a venture capital firm, from May 2005 until February 2011. From July 1998 to July 2003, Dr. Grais was a founder and executive vice president of SGX Pharmaceuticals Inc., a drug discovery company focusing on new treatments for cancer. Prior to that, she was a corporate attorney at Wilson Sonsini Goodrich & Rosati, where she practiced in such areas as venture financings, public offerings and strategic partnerships. Before practicing law, Dr. Grais worked as an assistant clinical professor of Internal Medicine and Critical Care at the University of California, San Francisco. She currently serves on the board of directors of ICON plc, a public contract research organization, Collective Health, a private healthcare services company and Iolyx Therapeutics, Inc., a private biotechnology company. Dr. Grais received a B.A. from Yale University, an M.D. from Yale Medical School and a J.D. from Stanford Law School. - Linda S. Grais，自2019年1月起担任Corvus Pharmaceuticals, Inc.董事会成员。Grais博士此前于2012年6月至2017年12月担任Ocera医疗公司总裁兼首席执行官，并于2008年1月至2017年12月担任公司董事会成员。在加入Ocera之前，Grais博士曾于2005年5月至2011年2月担任风险投资公司InterWest Partners的管理成员。从1998年7月到2003年7月，Grais博士是SGX Pharmaceuticals Inc.的创始人和执行副总裁，SGX Pharmaceuticals Inc.是一家专注于癌症新疗法的药物发现公司。在此之前，她是Wilson Sonsini Goodrich & Rosati的公司律师，在风险融资、公开发行和战略合作伙伴关系等领域执业。在从事法律工作之前，Grais博士曾在加州大学旧金山分校担任内科和重症监护的临床助理教授。她目前在公共合同研究机构ICON plc、私营医疗保健服务公司Collective Health和私营生物技术公司Iolyx Therapeutics，Inc.的董事会任职。Grais博士获得了耶鲁大学的学士学位、耶鲁大学医学院的医学博士学位和斯坦福大学法学院的法学博士学位。
- Linda S. Grais,has served as a member of Corvus Pharmaceuticals, Inc. Board since January 2019. Dr. Grais previously served as President and Chief Executive Officer of Ocera Therapeutics, Inc. from June 2012 to December 2017 and as a member of its board of directors from January 2008 through December 2017. Prior to her employment by Ocera, Dr. Grais served as a managing member at InterWest Partners, a venture capital firm, from May 2005 until February 2011. From July 1998 to July 2003, Dr. Grais was a founder and executive vice president of SGX Pharmaceuticals Inc., a drug discovery company focusing on new treatments for cancer. Prior to that, she was a corporate attorney at Wilson Sonsini Goodrich & Rosati, where she practiced in such areas as venture financings, public offerings and strategic partnerships. Before practicing law, Dr. Grais worked as an assistant clinical professor of Internal Medicine and Critical Care at the University of California, San Francisco. She currently serves on the board of directors of ICON plc, a public contract research organization, Collective Health, a private healthcare services company and Iolyx Therapeutics, Inc., a private biotechnology company. Dr. Grais received a B.A. from Yale University, an M.D. from Yale Medical School and a J.D. from Stanford Law School.
高管简历
中英对照 | 中文 | 英文- Leiv Lea
Leiv Lea，曾担任Corvus Pharmaceuticals， Inc.自2014年11月起担任首席财务官。Lea先生从2009年到2014年11月担任财务顾问。从1998年到2008年，Lea先生担任Pharmacyclics， Inc.（生物制药公司）的首席财务官。1996年至1997年，他担任财务顾问。1986年至1996年，他担任制冷设备制造商Margaux， Inc.的首席财务官。他获得了加州大学戴维斯分校的农业经济学学士学位和加州大学洛杉矶分校安德森学院的工商管理硕士学位。
Leiv Lea,has served as Corvus Pharmaceuticals, Inc. Chief Financial Officer since November 2014. Mr. Lea was a financial consultant from 2009 to November 2014. From 1998 to 2008, Mr. Lea served as Chief Financial Officer of Pharmacyclics, Inc., a biopharmaceutical company. From 1996 to 1997, he was a financial consultant. From 1986 to 1996, Mr. Lea served as Chief Financial Officer of Margaux, Inc., a refrigeration equipment manufacturer. He received a B.S. in Agricultural Economics from the University of California, Davis and an M.B.A. from the Anderson School at the University of California, Los Angeles.- Leiv Lea，曾担任Corvus Pharmaceuticals， Inc.自2014年11月起担任首席财务官。Lea先生从2009年到2014年11月担任财务顾问。从1998年到2008年，Lea先生担任Pharmacyclics， Inc.（生物制药公司）的首席财务官。1996年至1997年，他担任财务顾问。1986年至1996年，他担任制冷设备制造商Margaux， Inc.的首席财务官。他获得了加州大学戴维斯分校的农业经济学学士学位和加州大学洛杉矶分校安德森学院的工商管理硕士学位。
- Leiv Lea,has served as Corvus Pharmaceuticals, Inc. Chief Financial Officer since November 2014. Mr. Lea was a financial consultant from 2009 to November 2014. From 1998 to 2008, Mr. Lea served as Chief Financial Officer of Pharmacyclics, Inc., a biopharmaceutical company. From 1996 to 1997, he was a financial consultant. From 1986 to 1996, Mr. Lea served as Chief Financial Officer of Margaux, Inc., a refrigeration equipment manufacturer. He received a B.S. in Agricultural Economics from the University of California, Davis and an M.B.A. from the Anderson School at the University of California, Los Angeles.
- William B. Jones
William B. Jones，曾担任Corvus Pharmaceuticals， Inc.自2019年12月起担任药物开发高级副总裁，并担任Corvus Pharmaceuticals， Inc.2014年12月至2019年12月担任药物开发副总裁。2012年12月至2014年12月，他担任制药公司赛诺菲美国有限责任公司（Sanofi US， LLC）肿瘤学事业部的全球监管事务总监。从2008年到2012年3月，他担任Pharmacyclics， Inc.（生物制药公司）的项目管理和监管总监。2005年至2007年，他担任Plexxikon， Inc.（制药公司）的开发副总监。从2002年到2005年，他担任Vertex Pharmaceuticals， Inc.（生物技术公司）的高级项目经理。他持有Cincinnati大学的学士学位和化学博士学位，以及Babson College的工商管理硕士学位。他在牛津大学完成了博士后研究。
William B. Jones,has served as Corvus Pharmaceuticals, Inc. Senior Vice President, Pharmaceutical Development since December 2019 and as Corvus Pharmaceuticals, Inc. Vice President, Pharmaceutical Development from December 2014 to December 2019. Dr. Jones was Director of Global Regulatory Affairs in the oncology business unit of Sanofi US, LLC, a pharmaceutical company, from December 2012 to December 2014. From 2008 to March 2012, Dr. Jones was Director of Project Management & Regulatory at Pharmacyclics, Inc., a biopharmaceutical company. Dr. Jones served as Associate Director of Development for Plexxikon, Inc., a pharmaceutical company, from 2005 to 2007. From 2002 to 2005, he was Senior Project Manager at Vertex Pharmaceuticals, Inc., a biotechnology company. Dr. Jones received a B.S. and a Ph.D. in Chemistry from the University of Cincinnati and an M.B.A. from Babson College. He completed a post-doctoral fellowship at the University of Oxford.- William B. Jones，曾担任Corvus Pharmaceuticals， Inc.自2019年12月起担任药物开发高级副总裁，并担任Corvus Pharmaceuticals， Inc.2014年12月至2019年12月担任药物开发副总裁。2012年12月至2014年12月，他担任制药公司赛诺菲美国有限责任公司（Sanofi US， LLC）肿瘤学事业部的全球监管事务总监。从2008年到2012年3月，他担任Pharmacyclics， Inc.（生物制药公司）的项目管理和监管总监。2005年至2007年，他担任Plexxikon， Inc.（制药公司）的开发副总监。从2002年到2005年，他担任Vertex Pharmaceuticals， Inc.（生物技术公司）的高级项目经理。他持有Cincinnati大学的学士学位和化学博士学位，以及Babson College的工商管理硕士学位。他在牛津大学完成了博士后研究。
- William B. Jones,has served as Corvus Pharmaceuticals, Inc. Senior Vice President, Pharmaceutical Development since December 2019 and as Corvus Pharmaceuticals, Inc. Vice President, Pharmaceutical Development from December 2014 to December 2019. Dr. Jones was Director of Global Regulatory Affairs in the oncology business unit of Sanofi US, LLC, a pharmaceutical company, from December 2012 to December 2014. From 2008 to March 2012, Dr. Jones was Director of Project Management & Regulatory at Pharmacyclics, Inc., a biopharmaceutical company. Dr. Jones served as Associate Director of Development for Plexxikon, Inc., a pharmaceutical company, from 2005 to 2007. From 2002 to 2005, he was Senior Project Manager at Vertex Pharmaceuticals, Inc., a biotechnology company. Dr. Jones received a B.S. and a Ph.D. in Chemistry from the University of Cincinnati and an M.B.A. from Babson College. He completed a post-doctoral fellowship at the University of Oxford.
- Jeffrey Arcara
Jeffrey Arcara，自2024年2月起担任Corvus Pharmaceuticals, Inc.首席商务官。Arcara先生在2023年9月至2024年1月期间担任企业发展顾问。2011年至2023年8月，Arcara先生在制药公司梯瓦制药担任越来越多的职务，最近担任全球营销、投资组合和战略高级副总裁。2007年至2010年，他在制药公司Neuromed担任副总裁，业务发展。2006年至2007年，Arcara先生在制药公司Wyeth Pharmaceuticals，Inc.担任新产品营销执行董事，2000年至2005年在制药公司InKine Pharmaceuticals担任商业副总裁。Arcara先生获得了威斯康星大学麦迪逊分校的工商管理学士学位，以及加州大学洛杉矶分校安德森学院的工商管理硕士学位。
Jeffrey Arcara,has served as Corvus Pharmaceuticals, Inc. Chief Business Officer since February 2024. Mr. Arcara was a corporate development consultant from September 2023 to January 2024. From 2011 to August 2023 Mr. Arcara held roles of increasing responsibility with Teva Pharmaceuticals, a pharmaceutical company, most recently as Senior Vice President, Global Marketing, Portfolio and Strategy. From 2007 to 2010, he served as Vice President, Business Development at Neuromed, a pharmaceutical company. From 2006 to 2007 Mr. Arcara served as Executive Director, New Products Marketing at Wyeth Pharmaceuticals, Inc., a pharmaceutical company, and from 2000 to 2005 as Vice President, Commercial at InKine Pharmaceuticals, a pharmaceutical company. Mr. Arcara received a Bachelor of Business Administration degree from the University of Wisconsin Madison, and an M.B.A. from the Anderson School at the University of California, Los Angeles.- Jeffrey Arcara，自2024年2月起担任Corvus Pharmaceuticals, Inc.首席商务官。Arcara先生在2023年9月至2024年1月期间担任企业发展顾问。2011年至2023年8月，Arcara先生在制药公司梯瓦制药担任越来越多的职务，最近担任全球营销、投资组合和战略高级副总裁。2007年至2010年，他在制药公司Neuromed担任副总裁，业务发展。2006年至2007年，Arcara先生在制药公司Wyeth Pharmaceuticals，Inc.担任新产品营销执行董事，2000年至2005年在制药公司InKine Pharmaceuticals担任商业副总裁。Arcara先生获得了威斯康星大学麦迪逊分校的工商管理学士学位，以及加州大学洛杉矶分校安德森学院的工商管理硕士学位。
- Jeffrey Arcara,has served as Corvus Pharmaceuticals, Inc. Chief Business Officer since February 2024. Mr. Arcara was a corporate development consultant from September 2023 to January 2024. From 2011 to August 2023 Mr. Arcara held roles of increasing responsibility with Teva Pharmaceuticals, a pharmaceutical company, most recently as Senior Vice President, Global Marketing, Portfolio and Strategy. From 2007 to 2010, he served as Vice President, Business Development at Neuromed, a pharmaceutical company. From 2006 to 2007 Mr. Arcara served as Executive Director, New Products Marketing at Wyeth Pharmaceuticals, Inc., a pharmaceutical company, and from 2000 to 2005 as Vice President, Commercial at InKine Pharmaceuticals, a pharmaceutical company. Mr. Arcara received a Bachelor of Business Administration degree from the University of Wisconsin Madison, and an M.B.A. from the Anderson School at the University of California, Los Angeles.
- Richard A. Miller
Richard A. Miller，曾担任Corvus Pharmaceuticals， Inc.自2014年2月起担任Corvus Pharmaceuticals， Inc.的总裁兼首席执行官。自2014年1月起担任董事会成员，并共同创立了公司。从2012年4月到2014年10月，Miller博士担任Graphea， Inc.（他创立的私人控股化学公司）的董事长兼首席执行官。2010年9月至2011年12月，Miller博士担任The University of Texas at Austin的首席商业化官、副院长和化学研究教授。2009年1月至2011年2月，Miller博士创立了私人生物制药公司Principia Biopharma Inc.，并担任其总裁兼首席执行官和董事会成员。他曾担任Pharmacyclics， Inc.（一家公共生物制药公司）的总裁、首席执行官和董事（从1991年他共同创立该公司到2008年）。在Pharmacyclics， Miller博士领导了ibrutinib的最初发现和开发工作。Miller博士是IDEC制药公司（一家生物技术公司，于2003年6月与Biogen公司合并）的联合创始人、副总裁兼董事，在那里他领导了淋巴瘤的研究工作，导致了rituximab的开发。从1991年到2023年，Miller博士一直担任斯坦福大学医学中心的肿瘤学兼职临床教授。他持有Franklin & Marshall College的化学学士学位，以及New York State大学 Medical School的以优异成绩获得的医学博士学位。他是内科和肿瘤学的董事会认证。
Richard A. Miller,has served as Corvus Pharmaceuticals, Inc. President and Chief Executive Officer since February 2014 and chairman of Corvus Pharmaceuticals, Inc. Board since January 2014 and co-founded the Company. From April 2012 to October 2014, Dr. Miller was Chairman and Chief Executive Officer of Graphea, Inc., a privately held chemical company, which he founded. Dr. Miller served as Chief Commercialization Officer, Associate Dean and Research Professor in Chemistry at The University of Texas at Austin from September 2010 to December 2011. Dr. Miller founded Principia Biopharma Inc., a privately held biopharmaceutical company, and served as its President and Chief Executive Officer and a member of its board of directors from January 2009 to February 2011. He served as President, Chief Executive Officer and Director of Pharmacyclics, Inc., a public biopharmaceutical company, from 1991, when he co founded the company, to 2008. At Pharmacyclics, Dr. Miller led the initial discovery and development efforts for ibrutinib. Dr. Miller was a co founder, Vice President and Director of IDEC Pharmaceuticals Corporation, a biotechnology company that merged with Biogen, Inc. in June 2003, where he led research efforts on lymphoma leading to the development of rituximab. Dr. Miller has been Adjunct Clinical Professor of Medicine (Oncology) at Stanford University Medical Center from 1991 to 2023. Dr. Miller received a B.A. in Chemistry from Franklin & Marshall College and an M.D. summa cum laude from the State University of New York Medical School. He is board certified in both Internal Medicine and Medical Oncology.- Richard A. Miller，曾担任Corvus Pharmaceuticals， Inc.自2014年2月起担任Corvus Pharmaceuticals， Inc.的总裁兼首席执行官。自2014年1月起担任董事会成员，并共同创立了公司。从2012年4月到2014年10月，Miller博士担任Graphea， Inc.（他创立的私人控股化学公司）的董事长兼首席执行官。2010年9月至2011年12月，Miller博士担任The University of Texas at Austin的首席商业化官、副院长和化学研究教授。2009年1月至2011年2月，Miller博士创立了私人生物制药公司Principia Biopharma Inc.，并担任其总裁兼首席执行官和董事会成员。他曾担任Pharmacyclics， Inc.（一家公共生物制药公司）的总裁、首席执行官和董事（从1991年他共同创立该公司到2008年）。在Pharmacyclics， Miller博士领导了ibrutinib的最初发现和开发工作。Miller博士是IDEC制药公司（一家生物技术公司，于2003年6月与Biogen公司合并）的联合创始人、副总裁兼董事，在那里他领导了淋巴瘤的研究工作，导致了rituximab的开发。从1991年到2023年，Miller博士一直担任斯坦福大学医学中心的肿瘤学兼职临床教授。他持有Franklin & Marshall College的化学学士学位，以及New York State大学 Medical School的以优异成绩获得的医学博士学位。他是内科和肿瘤学的董事会认证。
- Richard A. Miller,has served as Corvus Pharmaceuticals, Inc. President and Chief Executive Officer since February 2014 and chairman of Corvus Pharmaceuticals, Inc. Board since January 2014 and co-founded the Company. From April 2012 to October 2014, Dr. Miller was Chairman and Chief Executive Officer of Graphea, Inc., a privately held chemical company, which he founded. Dr. Miller served as Chief Commercialization Officer, Associate Dean and Research Professor in Chemistry at The University of Texas at Austin from September 2010 to December 2011. Dr. Miller founded Principia Biopharma Inc., a privately held biopharmaceutical company, and served as its President and Chief Executive Officer and a member of its board of directors from January 2009 to February 2011. He served as President, Chief Executive Officer and Director of Pharmacyclics, Inc., a public biopharmaceutical company, from 1991, when he co founded the company, to 2008. At Pharmacyclics, Dr. Miller led the initial discovery and development efforts for ibrutinib. Dr. Miller was a co founder, Vice President and Director of IDEC Pharmaceuticals Corporation, a biotechnology company that merged with Biogen, Inc. in June 2003, where he led research efforts on lymphoma leading to the development of rituximab. Dr. Miller has been Adjunct Clinical Professor of Medicine (Oncology) at Stanford University Medical Center from 1991 to 2023. Dr. Miller received a B.A. in Chemistry from Franklin & Marshall College and an M.D. summa cum laude from the State University of New York Medical School. He is board certified in both Internal Medicine and Medical Oncology.